Legal & General Group
NAMS icon

Legal & General Group’s NewAmsterdam Pharma NAMS Stock Holding History

Legal & General Group’s Portfolio NAMS Stock Details NAMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.07M Sell
33,476
-7,475
-18% -$243K ﹤0.01% 2116
2025
Q4 		$1.44M Sell
40,951
-4,787
-10% -$174K ﹤0.01% 2102
2025
Q3 		$1.3M Buy
45,738
+1,503
+3% +$36K ﹤0.01% 2164
2025
Q2 		$801K Buy
44,235
+11,106
+34% +$203K ﹤0.01% 2298
2025
Q1 		$678K Buy
33,129
+10,183
+44% +$226K ﹤0.01% 2307
2024
Q4 		$590K Buy
22,946
+7,110
+45% +$151K ﹤0.01% 2402
2024
Q3 		$263K Hold
15,836
– – ﹤0.01% 2631
2024
Q2 		$304K Buy
+15,836
New +$318K ﹤0.01% 2598

Other funds holding NAMS

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
DFO
Duquesne Family Office New York $3.38B AUM 61.92% 1-Year Est. Return

Legal & General Group's NAMS Position: Q1 2026 in Review

Legal & General Group reduced its NewAmsterdam Pharma (NAMS) stake by 18% in Q1 2026, selling an estimated $243K and leaving 33,476 shares worth $1.07M. The position accounts for ﹤0.01% of the portfolio, ranked #2116.

Legal & General Group first reported a position in NAMS in Q2 2024 and has held it in 8 quarters since. The position peaked at $1.44M in Q4 2025. 171 funds tracked by Wall St. Rank hold NAMS as of Q1 2026.

  • Legal & General Group held 33,476 shares of NewAmsterdam Pharma worth $1.07M as of Q1 2026.
  • Legal & General Group sold 7,475 NewAmsterdam Pharma shares in Q1 2026, an estimated $243K.
  • NewAmsterdam Pharma made up ﹤0.01% of Legal & General Group's portfolio in Q1 2026, its #2116 holding.
  • Legal & General Group first reported a position in NewAmsterdam Pharma in Q2 2024 and has held it in 8 quarters since.
  • Legal & General Group's NewAmsterdam Pharma position peaked at $1.44M in Q4 2025.
  • 171 funds tracked by Wall St. Rank held NewAmsterdam Pharma as of Q1 2026.

Based on Legal & General Group's 13F filing for Q1 2026, filed 8 May 2026.